Edition:
United States

Xencor Inc (XNCR.OQ)

XNCR.OQ on NASDAQ Stock Exchange Global Market

24.40USD
20 Feb 2018
Change (% chg)

$-1.00 (-3.94%)
Prev Close
$25.40
Open
$25.26
Day's High
$25.47
Day's Low
$24.13
Volume
75,671
Avg. Vol
75,250
52-wk High
$28.62
52-wk Low
$18.67

Chart for

About

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials... (more)

Overall

Beta: 1.78
Market Cap(Mil.): $1,192.81
Shares Outstanding(Mil.): 46.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus

* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS

Jan 05 2018

BRIEF-Xencor Receives Milestone Payment From Amgen

* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN

Dec 05 2017

BRIEF-Xencor posts Q3 loss of $0.33 per share

* Xencor reports third quarter 2017 financial results and provides clinical pipeline update

Nov 07 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.01 -0.25
Novartis AG (NOVN.S) CHF80.46 +0.78
Roche Holding Ltd. (ROG.S) CHF223.90 +0.75
Roche Holding Ltd. (RO.S) CHF226.80 +0.80
AstraZeneca plc (AZN.L) 4,722.00 +9.50
GlaxoSmithKline plc (GSK.L) 1,325.00 +16.40
AbbVie Inc (ABBV.N) $117.98 -0.62
Bristol-Myers Squibb Co (BMY.N) $67.35 -1.61
Bristol-Myers Squibb Co (BMYMP.PK) $1,090.00 --
Amgen, Inc. (AMGN.OQ) $182.98 -0.57

Earnings vs. Estimates